Physician profile
Beverly Pennington
NPI 1558728014
$1,308.17
in general payments reported to CMS, 2019-2025
12 companies · $34.76 in 2025
The $34.76 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2023: $593 · 2024: $467 · 2025: $34.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.09 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $310.54 | 2021-2025 | Sogroya, Wegovy |
| Abbvie INC. | $214.77 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $210.18 | 2024 | Xarelto |
| Gilead Sciences, INC. | $121.86 | 2023 | Epclusa |
| Lilly USA, LLC | $118.51 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $110.36 | 2024 | Inspire |
| Mylan Specialty L.P. | $85.09 | 2023 | Yupelri |
| Abiomed | $39.31 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $34.98 | 2024 | |
| Aurinia Pharma U.S., INC. | $27.54 | 2023 | Lupkynis |
| Corcept Therapeutics | $21.14 | 2023 | Korlym |
| Amgen INC. | $13.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.